SpyBiotech, a biotechnology company pioneering novel vaccine platform technologies, today announced the appointment of Stuart Chaffee, PhD, as an independent member of its Board of Directors.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250729732969/en/
Stuart Chaffee, PhD, appointed to SpyBiotech's Board of Directors
Stuart Chaffee, currently Chief Executive Officer of QuantX Biosciences, brings over two decades of experience in the biotechnology and biopharma industry. He has played a pivotal role in the inception of four publicly traded biotechnology companies and has successfully raised over $900 million in private and public capital. In his previous operating role as Chief Business Officer at Affinivax, Inc., Chaffee was instrumental in driving the company's strategic growth, culminating in its acquisition by GSK for up to $3.3 billion. His expertise in business development and advising innovative biotech ventures positions him to provide invaluable strategic guidance as SpyBiotech advances its clinical pipeline and expands its proprietary SpyTag/SpyCatcher™ and other related protein superglue technology.
SpyBiotech's platform leverages the SpyTag/SpyCatcher system—a protein superglue that enables rapid, efficient, and stable antigen binding to vaccine delivery platforms. This technology offers a plug-and-play approach to vaccine development, minimizing risks while enhancing immunogenicity. The company recently completed vaccinations in its Phase I trial for SPYVLP01, a vaccine candidate targeting cytomegalovirus (CMV), underscoring the critical momentum towards addressing a pathogen that leads to chronic developmental health consequences.
"I am honored to join SpyBiotech’s Board at such an exciting juncture in the company’s journey," said Stuart Chaffee, PhD. "SpyBiotech’s innovative SpyTag/SpyCatcher platform and commitment to developing transformative vaccines align closely with my passion for patient-centric innovation. I look forward to contributing my experience to accelerate the company’s growth and bring these groundbreaking therapies to those who need them most."
"Stuart’s track record of building high-value biotech enterprises and navigating complex strategic landscapes makes him an outstanding addition to our Board," said Eddie Gray, Chairman of SpyBiotech. "His insights will be crucial as we propel our clinical programs forward and harness our unique technology to tackle some of the world’s most pressing health challenges. We are thrilled to welcome him to the team."
About SpyBiotech
SpyBiotech is a clinical-stage biotechnology company with novel vaccine platform technologies that can target infectious diseases, cancer, and chronic diseases. The company was spun out of the University of Oxford in 2017 backed by Oxford Science Enterprises (OSE) and Google Ventures (GV). Based on science developed at the University of Oxford, SpyBiotech’s novel vaccine platform is based on a proprietary protein “superglue” technology, which binds antigens to vaccine delivery platforms in a way that minimizes delivery risk and enhances immunogenicity and efficacy. This makes it ideal for use against infectious diseases in challenging environments, such as in the developing world, but also with potential application in non-infectious disease settings such as cancer. SpyBiotech has the exclusive rights from the University of Oxford to apply, commercialize and sub-license the SpyTag/SpyCatcher and related technology in vaccine development. www.spybiotech.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20250729732969/en/
SpyBiotech announces the appointment of Stuart Chaffee, PhD, as an independent member of its Board of Directors
Contacts
Media Contact:
Karen Sharma
ksharma@cglife.com